Knowledge and correct diagnosis of multivessel occlusion (MVO) prevalence in a cohort of ET candidates may affect treatment decisions and are relevant for trial inclusion or exclusion criteria. Whether additional exclusive or combined ET or intravenous thrombolysis (IVT) of coincidental occlusions in the other vessels is warranted remains unknown. A systematic investigation of a prospective database was performed to estimate the prevalence and localization of MVO in candidates subjected to angiography with an intention to perform ET. Hypothesis-generating explorative analysis was performed to assess associated factors.
L arge vessel occlusions (LVO) account for around every second to fourth acute ischemic stroke (AIS) admission, [1] [2] [3] and 10% to 15% of AISs occur in more than one territory. 4, 5 Endovascular therapy (ET) has recently evolved as the standard treatment for acute anterior circulation intracranial LVO. 6 Patients with LVO may present with additional thrombi within or distant from their target occluded territory.
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Methods
All consecutive patients directly admitted to our comprehensive stroke center and in whom endovascular treatment was intended were extracted from our prospective observational database (Bernese stroke registry, timeframe: January 2012 to July 2017). The registry was approved by the local ethics committee (Kantonale Ethikkommission für die Forschung Bern, Bern, Switzerland, amendment access number: 231/2014) and included baseline patients characteristics, risk factors, time metrics, and recorded clinical data. A standardized 3-month clinical follow-up visit was scheduled for each case. If the patient was unable to attend, a telephone interview was performed by a certified research nurse. After exclusion of patients with poor image quality (n=12), false-positive diagnosis of vascular occlusion (n=19), extracranial pathology only (n=6), and duplication of data (n=1), 720 patients remained for final analyses. One-hundred forty of 720 cases (19.4%) were also included into a recent publication regarding this topic (cohort overlap). 7 Analysis is displayed in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology guidelines. 8 The raw patient-level data that support the findings of this study are available from the corresponding author on reasonable request and after clearance by the local ethics committee.
Image Analysis
Initial diagnostic workup consisted of either standardized 1.5T/3T magnetic resonance imaging (n=415, Magnetom Avanto or Magnetom Verio, Siemens, Erlangen, Germany) or computed tomography (CT; n=246, SOMATOM Definition Edge, Siemens). In 38 and 21 cases, respectively, CT was followed by magnetic resonance imaging and vice versa. Magnetic resonance imaging sequences consisted of axial fluid-attenuated inversion recovery, diffusion weighted imaging, susceptibility weighted imaging, intracranial time-of-flight angiography, contrast-enhanced cervical angiography, gradient-echo dynamic susceptibility contrast perfusion ±T1-weighted post-contrast. Scanner parameters for magnetic resonance perfusion were as follows: repetition time: 1410 ms, echo time: 30 ms, field of view: 230×230 mm, voxel size: 1.8×1.8×5.0 mm, slice thickness: 5.0 mm, number of slices: 19, and flip angle: 90°. Respective relative cerebral blood volume, relative cerebral blood flow, mean transit time, and time-to-peak maps were generated using the Olea Sphere Software environment (Olea Sphere v2.3; Olea Medical, La Ciotat, France). CT included thin slice noncontrast CT (slice thickness: 1 mm), perfusion CT (automatically processed by the scanner software syngo.via, Siemens), and CT angiography in early arterial (bolus triggered, slice thickness: 0.6 mm) and late venous phase (75 seconds delay, slice thickness: 1 mm). All images were reevaluated by a certified neuroradiologist with at least 3 years of experience. For the final decision on the presence of MVO, all available sequences were reviewed. Whole-brain digital subtraction angiography (DSA) images acquired before the intervention were used to confirm the suspected occlusion(s). Preinterventional 3-vessel angiography was performed as standard routine clinical practice to assess cross-flow and collaterals. According to standard operating protocols, preinterventional diagnostic angiography has to be performed within 3 minutes; otherwise, it was discontinued, and direct transition to endovascular stroke treatment was pursued (<10 cases). In almost all cases, a minimum of 3 vessels were selectively injected, including bilateral CCAs and left or right vertebral arteries in accordance with our routine clinical practice. In cases of occlusion site discrepancies between initial diagnostic workup and first DSA runs (eg, clot fragmentation after IVT), the case was not rated as initial MVO. In cases of MVO, the primary target occlusion was defined as the occlusion site on CT or magnetic resonance imaging deemed responsible for the clinical symptoms toward which endovascular treatment was intended. If the second occlusion was within the territory of and distal to the primary target occlusion, this was rated as downstream MVO (see examples denoted in Figure 1 and Figure I in the online-only Data Supplement). All other MVOs were rated as MVO in different territories (see examples denoted in Figure 2 and Figure II in the online-only Data Supplement). Downstream MVO was confirmed by DSA whenever possible, for example, good collateralization, incomplete primary occlusion, and microcatheter injection after first pass of the primary occlusion site or during stentretriever deployment (Figure 1 ). To ensure adequate classification of downstream MVO, cases without possible confirmation by DSA were reevaluated by 2 additional neuroradiologists with at least 5 years of experience before reaching consensus. To distinguish acute from chronic coincidental MVOs (false-positive classification), perfusion maps and recanalization status at 3 months were compared with the pretherapeutic CT or magnetic resonance imaging workups. MVO was rated as of possible common cervical origin whenever an ipsilateral large or fetal Pcom or A1 segment proximal to the primary target occlusion could have served to distribute a fraction of the same thromboembolic load in another territory, for example, MVO of possible common internal carotid artery (ICA) origin in case of concomitant ipsilateral M2 and anterior cerebral artery occlusions or M1 and P3 occlusion. Hemorrhagic transformations were evaluated on 24 to 48-hour follow-up imaging and were considered symptomatic intracerebral hemorrhages (sICH) if they were associated with worsening by ≥4 points on the National Institutes of Health Stroke Scale (NIHSS) or prompted death.
Endovascular Treatment
Institutional guidelines of acute stroke patient care and eligibility criteria for endovascular treatment can be found online (http://www. neurologie.insel.ch/fileadmin/neurologie/neurologie_users/Unser_ Angebot/Dokumente/Stroke_Guidelines_2018.pdf). Intra-arterial thrombolysis with urokinase as stand-alone therapy was used in 85 
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cases (11.8%). No intervention was performed in 74 cases (10.3%) because of difficult access or preinterventional reperfusion on DSA before the start of endovascular treatment. All other cases were treated with second-generation thrombectomy devices with or without intraarterial urokinase (>90% Solitaire or Capture, size 4-6/20-40 mm or 3/15 mm, respectively; Medtronic, Ireland). Endovascular procedures were typically performed without intravenous heparin through a 20-cm-long 8 or 9F sheath under local or general anesthesia, depending on patient cooperation and comorbidities. A diagnostic DSA of at least 3 vessels, including both common carotid arteries and one or both vertebral arteries, was initially executed using a 5F catheter, followed by placement of an 8 or 9F balloon-guide catheter whenever possible (or a 6 or 8F long sheath±intermediate catheter at the operator's discretion) before navigating a microcatheter (Prowler select+ 0.021 inch; Cordis, Johnson and Johnson) over a 0.012-to 0.016-inch microwire (such as the Silverspeed, Cordis, Johnson and Johnson, or Traxcess; Microvention-Terumo, Tustin, CA) to the primary target occlusion site. A stent retriever was deployed after microcatheter injection confirmed appropriate position distal to the thrombus. A further contrast injection from the guide catheter was performed to assess the presence of a bypass effect before attempting to retrieve the clot under proximal aspiration with flow arrest or reversal. Number of passes of the primary and secondary target occlusion sites were recorded, as well as the final modified Thrombolysis in Cerebral Infarction (TICI) grade, with mTICI 2b defined ≥50% reperfusion of the initially occluded target territory.
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Statistical Analysis
Statistical comparisons of unpaired data were performed using Welch t test for independent samples, Mann-Whitney U test, or Fisher exact test, as appropriate. The significance level was chosen to be α=0.05. 95% confidence intervals (CIs) of frequency counts were evaluated using the asymptotic Wald method based on a normal approximation. An explorative analysis of factors associated with MVO was performed using multivariable logistic regression with inclusion of variables with P<0.15 in univariate comparisons. Variables included into univariate comparisons are denoted in Table. Results were displayed as adjusted odds ratios (aOR) and 95% CIs. For adjustment of categorical variables, deviance was used as contrast method (implementing the last category as reference). Multivariable logistic regression was then repeated applying a backward likelihood ratio model to assess robustness of the found associations. Analyses regarding technical success were controlled for occlusion site, IVT, access difficulties, and intra-arterial (IA) thrombolysis only stent-retriever thrombectomy. Adjustment for confounders regarding functional outcome was performed by including patient age, preadmission functional independence (modified Rankin Scale score ≤2), admission NIHSS score, IVT, occlusion site, time from symptom onset/last-seen-well to first diagnostic angiography run, and final mTICI score into the model. Patients with missing modified Rankin Scale score at 3 months were excluded from these analyses (41/720, 5.7%). Statistical analysis was performed using IBM SPSS statistics version 21 (IBM, Armonk, NY).
Results
In (Table) . A detailed overview of all cases with multiple occlusions can be found in the Table I in the online-only Data Supplement and a simplified overview on occlusion site combinations is displayed in Figure 3 . In 42 of 77 (54.5%) cases, the accompanying occlusions were not described in the initial acute imaging report (nonreport rate: 28/50 in different territories, 14/27 in downstream territories). Patients with multiple occlusions had higher baseline systolic blood pressure (median 169 versus 153 mm Hg; P<0.001) and a different distribution of primary occlusions (P value for overall difference=0.003). Furthermore, the frequency of statin treatment tended to be lower in the multiple occlusion group (50.6% versus 61.0%; P=0.086). There were no statistically significant differences regarding admission NIHSS score (14 versus 15; P=0.411), prior medication with oral anticoagulants (9.2% versus 7.8%; P=0.835), or aspirin (31.6% versus 36.4%; P=0.438) between non-MVO and MVO patients. Pathogenic mechanism did not differ between both groups (P=0.681). In multivariable logistic regression analysis, only statin treatment (aOR, 0.477; 95% CI, 0.276-0.827), higher admission systolic blood pressure (aOR for 1 mm Hg-increase, 1.014; 95% CI, 1.005-1.023), and primary occlusion site at M2 (aOR, 1.870; 95% CI, 1.103-3.170) were significantly related to multiple occlusions. Comparable estimates were found when using a backward likelihood ratio model (Table) . Adjusted predicted probabilities with respect to increasing admission systolic blood pressure are denoted in Figure III in the online-only Data Supplement.
MVO patients had lower rates of successful reperfusion at the primary occlusion site (59.7% versus 75.3%; P=0.006; Table II in the online-only Data Supplement), especially mTICI 3 scores (27.3% versus 39.8%; P=0.035). The latter effect was mainly seen in patients with downstream occlusions (n=27; mTICI 3 18.5% versus 39.8%; P=0.027). It was not statistically tangible in patients with coincidental occlusions in different territories (n=50; mTICI 3 32.0% versus 39.8%; P=0.297). Overall, the association of MVO with lower rates of successful reperfusion remained statistically significant after adjusting for intravenous tPA (tissue-type plasminogen activator), site of occlusion, access difficulties, and intra-arterial tPA only (aOR, 0.549; 95% CI, 0.316-0.953; P=0.033) but not for mTICI 3 reperfusion (aOR, 0.648; 95% CI, 0.362-1.160; P=0.144). Although there were no differences regarding the prevalence of sICH between both groups (5.2% versus 3.9%; P=0.539), MVO patients had lower rates of good functional outcome at day 90 (modified Rankin Scale score ≤2; 26.4% versus 45.6%; P=0.002) and higher 90-day mortality (44.4% versus 22.6%; P<0.001; Table II in the online-only Data Supplement). MVO remained significantly associated with lower rates of good functional outcome at day 90 after adjusting for age, baseline NIHSS score, baseline functional independence, occlusion site, intravenous tPA, time from symptom-onset/last-seenwell to first DSA image, and final mTICI score (aOR, 0.437; 95% CI, 0.207-0.923; P=0.030; n=537). To ensure that this association is not an artificial observation in n=537 cases, logistic regression analysis was rerun excluding variables with missing data points (time to first DSA image and baseline functional independence). In this model, a comparable point estimate was observed (aOR, 0.401; 95% CI, 0.200-0.804; P=0.010). 
Discussion
This study has 4 major findings: (1) every 10th AIS patient with LVO subjected to angiography for endovascular treatment experiences MVO within or distant from the primary occluded territory, (2) MVO is prospectively overlooked in almost half of the cases before endovascular treatment has begun, (3) patients with high systolic blood pressure and without current statin intake may be at higher risk of MVO, and (4) occurrence of MVO has implications for therapy success and patient outcome.
Prevalence and Pathogenesis
MVO have been described in other acute embolic diseases such as myocardial infarction, albeit extremely rarely (around NI represents that the thrombus length was not included because of high interdependency with occlusion site; witnessed symptom onset to first imaging was not included because of the large amount of missing data points (artificial case restriction). VE represents that the variable excluded based on backward likelihood ratio model. aOR indicates adjusted odds ratio; CT, computed tomography; ICA, internal carotid artery; IV tPA, intravenous tissue-type plasminogen activator; M1/M2, segment 1/2 of the middle cerebral artery; MRI, magnetic resonance imaging; mRS, modified Rankin Scale; NI, not included because of interdependency with primary intracranial occlusion site; NIHSS, National Institutes of Health Stroke Scale; OAC, oral anticoagulant; TIA, transient ischemic attack; TOAST, Trial of ORG 10172 in Acute Stroke Treatment; and VE, variable excluded by backward likelihood ratio. *P<0.05. †P<0.01. 60 cases published). 10 In this analysis of 720 consecutive AIS patients with LVO subjected to DSA in the context of intended endovascular treatment, the prevalence of MVO was 10.7%. Generally, multiple intracerebral emboli are thought to arise from unstable thromboembolic sources and are predicative of stroke recurrence at day 90. 11 In our series, however, we did not find a specific correlation between MVO occurrence and pathogenic stroke mechanism. Moreover, recent echocardiographic analyses failed to demonstrate more frequent aortic or cardiac embolic sources in patients with acute strokes involving different territories: internal carotid artery left versus internal carotid artery right versus vertebrobasilar. 12 According to our data, patients with MVO presented with higher arterial systolic blood pressures compared with patients with singlevessel occlusions. This association was considerably robust and remained significant in multivariable logistic regression, even when corrected for multiple comparisons (data not shown). However, it is important to stress that no definitive conclusion can be drawn regarding the causality of this association. Indeed, MVO causes greater ischemic damage than single vessel occlusions, which may trigger a more intense autoregulatory hypertensive response. 13 On the contrary, it is conceivable that higher systolic blood pressure may facilitate MVO by increasing the risk of clot fragmentation once it is lodged at a cervical or intracranial bifurcation. The finding of isolated systolic blood pressure increase in MVO patients rather than diastolic values may support this. It has been calculated that clots occluding major cerebral arteries experience a mean arterial pressure of ≈75 mm Hg with ±20% of pulsatility on their proximal side.
14 Evidence from computational clot lysis models have found an association between higher blood pressure and risk of early fragmentation. 15 Furthermore, pressure within the circle of Willis is highest at the terminal internal carotid artery, 16 implying that the higher frequency of combined middle cerebral artery and anterior cerebral artery occlusions might result from carotid-T fragmentation. Future studies are necessary to assess the true interdependence of high systolic blood pressure and MVO occurrence.
Impact on Angiographic Success and Clinical Outcome
Downstream MVO impedes reperfusion success in patients receiving ET. This is not surprising, considering the fact that they represent distally fragmented emboli in the same territory that are much more difficult to remove completely, explaining why unsuccessful (mTICI 2a) or moderately successful (mTICI 2b) rather than completely successful reperfusion (mTICI 3) is the rule, despite recanalization of the more proximal primary target occlusion. Although the clinical importance of unsuccessful and successful reperfusion is selfevident, 17 a distinctively different outcome between mTICI 2b and mTICI 3 cases was recently reported. 18 Additionally, MVO was not only related to poorer angiographic success but also to worse functional outcome, as previously reported, 4 even after adjusting for postprocedural mTICI scores. Finally, shutdown of collateral circulation by one or several concomitant occlusions distal to the primary occlusion site may further explain worse outcome in downstream MVOs. 7 
Further Implications
The presented results also have implication in light of future and currently enrolling endovascular stroke trials. The value of IVT before ET in single proximal LVOs remains undetermined [19] [20] [21] [22] and is currently being investigated in 2 randomized controlled trials (SWIFT DIRECT [Solitaire With the Intention for Thrombectomy Plus Intravenous t-PA Versus DIRECT Solitaire Stent-Retriever Thrombectomy in Acute Anterior Circulation Stroke], trial registration number: NCT03192332 and MR CLEAN-NO IV [Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands investigating the added benefit of intravenous alteplase prior to intra-arterial thrombectomy in stroke patients with an intracranial occlusion of the anterior circulation], trial registration number: ISRCTN80619088). Because secondary occlusions in MVO are usually located in the distal vascular bed, it seems that IVT should not be withheld in these patients, given its high potency to successfully lyse small peripheral clots. This may hold equally true for downstream occlusions when retrograde collateralization is sufficient. Interestingly, MVO has not been reported in the pivotal thrombectomy trials or in recent large cohort registries including up to 1000 patients. 23, 24 In light of the present report, MVO should be carefully assessed before including LVO patients in future randomized controlled trials. As endovascular techniques continue to evolve, new endovascular options may enable a safer mechanical approach for coincidental occlusions in the future, and intra-arterial thrombolysis may be considered in distal concomitant occlusions, once an intracranial access was already established anyway. For the time being, however, it seems that this subset of patients might strongly benefit more from a bridging approach until proven otherwise. Last, and in light of discussions regarding the evaluation of thrombus fragmentation during thrombectomy maneuvers, it should be noted that ≈4% of LVO patients present with a second, more distally located downstream thrombus before the intervention begins.
Limitations
This study has several limitations mainly because of its retrospective design and confinement to a cohort of endovascular candidates. Moreover, the true overall prevalence of MVO in an unselected cohort remains to be determined. The strength of confine our analysis with an intention for endovascular reperfusion, on the contrary, was the possibility to confirm MVOs on gold-standard DSA. Another limitation is the questionable association of statin pretreatment and systolic blood pressure with MVO, which requires external validation. Although interpreting baseline high blood pressure and statin pretreatment as causative for MVO may be tempting, it remains beyond the scope of this study. Finally, further research is necessary to assess whether CT or magnetic resonance imaging (with or without perfusion studies) is more accurate to correctly diagnose MVO prospectively, because such findings are under-reported and often overlooked at the acute stage preceding ET.
Conclusions
Every tenth AIS patient with a LVO subjected to angiography for endovascular treatment presents with another vessel occlusion within or distant from the primary occluded territory. Such coincidental occlusions are overseen in approximately half of the cases on the initial CT or magnetic resonance imaging diagnostic workup, which may complicate therapeutic decision making, because MVO tends to be associated with decreased endovascular success and worse clinical outcome. Moreover, patients with MVO presented with higher baseline systolic blood pressure and were less often pretreated with statins, observations warranting external validation and further assessment.
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